80 completed. 80 Phase 2, 13 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 80 | Completed 80 |
| Phase 1 | 13 | Completed 13 |
| Phase 3 | 4 | Completed 4 |
Follow Alcohol Use Disorder: new trials by email Literature Review of Alcohol Use Disorder trials Research Report on Alcohol Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder Mazdutide, Placebo - Alcohol Use Disorder | Phase 2 | Completed | Eli Lilly and Company | 308 | 2025-02-06 | 2026-07-16 |
| Study of Sunobinop on Craving in Alcohol Use Disorder Sunobinop, Placebo to match sunobinop - Alcohol Use Disorder | Phase 2 | Completed | Knoa Pharma LLC | 40 | 2025-01-28 | 2026-07-07 |
| Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder Sunobinop, Placebo to match sunobinop - Alcohol Use Disorder | Phase 2 | Completed | Knoa Pharma LLC | 209 | 2024-10-14 | 2026-06-05 |
| MDMA for AUD/PTSD Comorbidity MDMA - Alcohol Use Disorder, Post Traumatic Stress Disorder | Phase 2 | Completed | Carolina L Haass-Koffler | 22 | 2024-02-06 | 2026-09-11 |
| Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD) Semaglutide 3 MG [Rybelsus], Semaglutide 7 MG [Rybelsus], Placebo - Alcohol Use Disorder | Phase 2 | Completed | University of Colorado, Denver | 50 | 2024-01-11 | 2025-12-26 |
| Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1 Spironolactone - Alcohol Use Disorder, Hiv | Phase 2 | Completed | Yale University | 21 | 2023-11-06 | 2026-06-16 |
| Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder Psilocybin, Maltodextrin - Alcohol Use Disorder | Phase 2 | Completed | Anders Fink-Jensen, MD, DMSci | 60 | 2023-09-01 | 2026-03-24 |
| Testing a Novel Therapeutic Strategy for Comorbid Post-Traumatic Stress Disorder and Alcohol Use Disorder Propranolol, Placebo - Stress Disorders, Post-Traumatic, Alcohol Use Disorder | Phase 2 | Completed | Centre for Addiction and Mental Health | 48 | 2023-07-15 | 2026-06-15 |
| Semaglutide Therapy for Alcohol Reduction - Tulsa Semaglutide, Placebo - Alcohol Use Disorder | Phase 2 | Completed | Oklahoma State University Center for Health Sciences | 80 | 2023-07-07 | 2025-12-17 |
| Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity? Semaglutide Injectable Product, Placebo - Alcohol Abuse, Alcohol Addiction | Phase 2 | Completed | Psychiatric Centre Rigshospitalet | 108 | 2023-06-13 | 2025-08-05 |
| An Open-Label, Single Dose Study in Patients With Alcohol Use Disorder BPL-003 - Alcohol Use Disorder | Phase 2 | Completed | Beckley Psytech Limited | 13 | 2023-05-30 | 2026-05-22 |
| Integrated Digital Intervention for Alcohol Use Disorder Mobile health application, Medical Management - Alcohol Use Disorder | Phase 2 / Phase 3 | Completed | Quit Genius | 242 | 2023-01-01 | 2025-11-20 |
| Cannabidiol in Youth Alcohol Use Disorder Cannabidiol - Alcohol Use Disorder | Phase 2 | Completed | Medical University of South Carolina | 36 | 2022-10-01 | 2025-08-14 |
| Semaglutide for Alcohol Use Disorder Semaglutide, Sham/placebo - Alcohol Use Disorder, Cigarette Smoking | Phase 2 | Completed | University of North Carolina, Chapel Hill | 48 | 2022-09-02 | 2025-04-02 |
| Intranasal Oxytocin for the Treatment of Alcohol Use Disorder Instranasal Oxytocin - Alcohol Use Disorder, Alcohol Misuse | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 100 | 2022-06-29 | 2025-08-07 |
| Effects of Pioglitazone on Stress Reactivity and Alcohol Craving Pioglitazone, Placebo - Alcohol Use Disorder | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 67 | 2022-05-12 | 2025-08-27 |
| Effect of Endotoxin on Alcohol Consumption Endotoxin - Alcohol Use Disorder | Phase 2 | Completed | Yale University | 27 | 2022-02-27 | 2025-11-03 |
| Enhancing the Effects of Alcohol Treatment With Lamotrigine Lamotrigine, Placebo - Alcohol Use Disorder | Phase 2 | Completed | Brown University | 44 | 2022-01-24 | 2025-06-13 |
| Human Laboratory Study of ASP8062 for Alcohol Use Disorder ASP8062, Placebo - Alcohol Use Disorder, Alcohol Drinking | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 60 | 2021-12-13 | 2024-12-03 |
| Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder Oxytocin nasal spray, Naltrexone Pill, Placebo - Alcohol Use Disorder, Alcoholism | Phase 2 / Phase 3 | Completed | Central Institute of Mental Health, Mannheim | 62 | 2021-12-02 | 2024-03-29 |
Showing 20 of 80. Sign in to see all of them.
Alcoholism (80) · Alcohol Drinking (8) · Stress Disorders, Post-Traumatic (6) · Alcohol-Related Disorders (5) · Depressive Disorder, Major (5) · Substance-Related Disorders (5) · Behavior, Addictive (3) · Anxiety Disorders (2) · Drinking Behavior (2) · Marijuana Abuse (2) · Acquired Immunodeficiency Syndrome (1) · Alcohol Abstinence (1) · Alcohol-Induced Disorders (1) · Alcoholic Intoxication (1) · Attention Deficit Disorder with Hyperactivity (1)
Chemically-Induced Disorders (79) · Mental Disorders (79) · Alcohol-Related Disorders (75) · Substance-Related Disorders (75) · Behavior (13) · Drinking Behavior (6) · Mood Disorders (6) · Stress Disorders, Traumatic (6) · Trauma and Stressor Related Disorders (6) · Depressive Disorder (5) · Compulsive Behavior (3) · Impulsive Behavior (3) · Pathological Conditions, Signs and Symptoms (3) · Communicable Diseases (2) · Disease Attributes (2)
Sugars (8) · Naltrexone (7) · Oxytocin (4) · Sodium Chloride (4) · Varenicline (4) · semaglutide (4) · Cannabidiol (3) · Ethanol (3) · Gabapentin (3) · Acamprosate (2) · Acetylcysteine (2) · Endotoxins (2) · Ketamine (2) · Mirtazapine (2) · Pioglitazone (2)
Medical University of South Carolina (9) · University of California, Los Angeles (7) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (5) · The Scripps Research Institute (3) · University of Colorado, Denver (3) · Brown University (2) · Centre for Addiction and Mental Health (2) · Knoa Pharma LLC (2) · NYU Langone Health (2) · New York State Psychiatric Institute (2) · The University of Texas Health Science Center, Houston (2) · University of Pittsburgh (2) · VA Connecticut Healthcare System (2) · Yale University (2) · Alkermes, Inc. (1)
United States (67) · Bulgaria (2) · Canada (2) · Denmark (2) · France (2) · Switzerland (2) · Germany (1) · Poland (1) · Romania (1) · Russia (1) · Sweden (1) · United Kingdom (1)
Lara Ray, PhD (5) · Barbara J. Mason, Ph.D. (3) · Gihyun Yoon, MD (2) · Jack R Cornelius, M.D., M.P.H. (2) · Joseph P Schacht, PhD (2) · Raymond F Anton, MD (2) · Robert Miranda, PhD (2) · Ahmed Hassan, MD (1) · Alain Puech (1) · Anders Fink-Jensen, MD, DMSc (1) · Anders Fink-Jensen, Professor (1) · Charles Marmar, MD (1) · Christian Hendershot, Ph.D. (1)
PMID 15850502, PMID 19032530, PMID 19345510, PMID 22439295, PMID 27920321, PMID 29336496, PMID 29379114, PMID 29540927, PMID 30538599, PMID 32150232, PMID 32160422, PMID 32368793, PMID 32912290, PMID 33225963, PMID 34080890, PMID 34092158, PMID 34256607, PMID 34585396, PMID 34968106, PMID 35410938, PMID 35523943, PMID 36241352, PMID 36646315, PMID 38126709, PMID 38206930, PMID 38597214, PMID 38828963, PMID 39225670, PMID 39262902, PMID 39719161, PMID 39739971, PMID 39779270, PMID 39937469, PMID 40080609, PMID 40123107, PMID 40144690, PMID 40305022, PMID 40357520, PMID 40487775, PMID 40500407, PMID 40795937, PMID 41016625, PMID 41603979, PMID 42070571, PMID 42236678, PMID 42458234
2015 (1), 2017 (1), 2018 (1), K24AA026326 (1), P01AA029545 (1), P50AA010761 (1), P50AA027055 (1), P50DA009262 (1), P50DA012756 (1), R01AA021744 (1), R01AA022309 (1), R01AA024933 (1), R01AA025365 (1), R01AA025930 (1), R01AA026190 (1)